Arthritis drugs could prolong livesUsay CompareResearchers from the German Rheumatism Centre in Berlin looked at the death rates of 9000 sufferers of the condition and found that rituximab could lower …and more »
TRAPIANTI, BELATACEPT MANTIENE LA FUNZIONE RENALESalusBelatacept è il primo bloccante selettivo della co-stimolazione delle cellule T approvato per la profilassi del rigetto dell'organo in pazienti sieropositivi al virus di Epstein-Barr (EBV) che …
Telegraph.co.ukLittle-used arthritis drugs could prolong lifeTelegraph.co.ukPatients taking rituximab, another type of biologic treatment, had about a 40 per cent lower chance of dying than those who had only taken DMARDS. Researchers from the German R…
Bristol-Myers Squibb reveals NULOJIX dataCSL RecruitmentNULOJIX is the first selective T-cell costimulation blocker for the prophylaxis of organ rejection in adults with Epstein-Barr Virus who are having a kidney transplant in conjunction with basilixi…
NCI Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment …MarketWatch (press release)The results (detailed in Abstract #2528), reported in a poster presented by the NCI, demonstrated that vaccination following rituximab combinat…
Control of disease activity and biologic treatment increase life expectency in …Medical XpressThe study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab…
生物谷 (新闻发布)PNAS：证实一些干细胞也能触发肿瘤生长生物谷 (新闻发布)Sci Transl Med：daclizumab调控调节性T细胞促进肿瘤免 · Ann Intern Med：研究发现六成妇女过度乳房X光检查 · Nat C…
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical …Healthcare Global (press release)SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits of TREAKISYM(R) (Bendamustine) in Combination With Rituximab in Patient…
New Treatment Option for Non-Hodgkin Lymphoma Delays Tumour Progression With …MarketWatch (press release)A trial that enrolled 549 patients with certain types of immune system cancers showed that bendamustine and rituximab worked better and was less …
Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions …PipelineReview.com (press release)Both patient groups received basiliximab induction, MMF and corticosteroids. Both studies excluded recipients undergoing first transplant w…